Company Overview

Nanalysis Scientific Corp. is a Canadian technology company focused on compact nuclear magnetic resonance (NMR) spectroscopy and magnetic resonance imaging (MRI) technologies for industrial, research, and healthcare-related applications. The company operates primarily in the scientific instrumentation and analytical technology industries, developing and commercializing benchtop NMR spectrometers designed to provide lower-cost, portable, and easier-to-operate alternatives to traditional high-field laboratory systems. Its products are used by academic institutions, pharmaceutical companies, chemical manufacturers, energy companies, food testing laboratories, and industrial process operators.

The company’s primary revenue drivers include sales of analytical instruments, recurring service and maintenance agreements, consumables, software, and related scientific services. Through acquisitions and internal development, Nanalysis has expanded beyond core NMR instrumentation into broader laboratory services and imaging-related technologies. The company originated from research and development work in compact magnetic resonance systems and evolved into a publicly traded instrumentation company listed on the TSX Venture Exchange under the symbol NSCI. Its positioning centers on portability, lower operating costs, and accessibility compared with conventional superconducting NMR systems that require cryogens and specialized infrastructure.

Business Operations

Nanalysis generates revenue through a combination of instrument sales, laboratory services, software-enabled analytical solutions, and recurring customer support contracts. Its major operating activities include the development and commercialization of compact NMR spectrometers under the Nanalysis platform, as well as analytical testing and imaging services through acquired subsidiaries. The company has also expanded through acquisitions into complementary scientific and industrial service businesses, including laboratory testing operations and MRI-related technologies. Public disclosures indicate that recurring service and support revenue has become an increasingly important component of the business model.

The company operates in both domestic and international markets, with commercial activities spanning North America, Europe, and selected global industrial markets. Nanalysis controls proprietary magnetic resonance technology, instrument design capabilities, software systems, and related intellectual property tied to compact permanent magnet-based NMR systems. Notable subsidiaries and acquisitions associated with its expansion strategy include K'Prime Technologies, RS2D, and Quad Systems AG, which broadened the company’s exposure to MRI electronics, scientific instrumentation, and imaging technologies. Data regarding the exact contribution of each subsidiary to consolidated revenue is limited in public disclosures and may vary by reporting period.

Strategic Position & Investments

Nanalysis has pursued a strategy centered on expanding the adoption of compact magnetic resonance technologies while building a diversified scientific instrumentation and services platform. Growth initiatives have included acquisitions, increased recurring revenue generation, expansion into industrial process monitoring, and the integration of imaging and electronics capabilities. The company has also emphasized opportunities in decentralized laboratory analysis, pharmaceutical quality control, energy applications, and industrial automation environments where portability and lower infrastructure requirements provide competitive advantages.

Major investments and acquisitions have strengthened the company’s capabilities in MRI electronics, spectroscopy systems, and analytical services. The acquisition of RS2D added MRI and scientific electronics expertise, while Quad Systems AG contributed engineering and imaging-related capabilities. Nanalysis has also invested in expanding its installed instrument base and distribution channels internationally. The company continues to participate in emerging analytical technology markets tied to compact instrumentation, automation, and applied magnetic resonance technologies for industrial and research applications.

Geographic Footprint

Nanalysis is headquartered in Calgary, Alberta, Canada, and maintains operations and commercial activities across multiple international regions. Its customer base spans North America, Europe, and other international scientific and industrial markets through direct sales, distributors, and subsidiary operations. The company’s acquisition strategy has increased its operational presence outside Canada, particularly in European instrumentation and imaging technology markets.

The company’s products are used globally by universities, industrial laboratories, pharmaceutical organizations, petrochemical companies, and research institutions. Through subsidiaries and partnerships, Nanalysis has expanded its influence in scientific instrumentation markets that require compact analytical systems and MRI-related technologies. Publicly available information confirms international commercial exposure, although detailed country-level revenue segmentation is limited in some reporting periods.

Leadership & Governance

Nanalysis was founded by individuals associated with the development and commercialization of compact magnetic resonance technologies in Canada. The company is governed by a board of directors and executive leadership team focused on expanding recurring revenue streams, scaling scientific instrumentation businesses, and integrating acquired operations into a broader analytical technology platform. Leadership communications in public filings and investor materials emphasize disciplined acquisition growth, technological innovation, and long-term expansion in analytical instrumentation markets.

Key executives include:

• Sean Krakiwsky – Founder, President and Chief Executive Officer
• Ryan Riess – Chief Financial Officer
• Ming Chiao – Chairman of the Board
• David J. Rolfe – Director
• Claude Cohen-Bacrie – President of RS2D

Leadership strategy has consistently focused on expanding the company’s installed base of compact NMR systems, building recurring service revenue, and integrating acquired imaging and instrumentation businesses into a broader scientific technology ecosystem. Some executive responsibilities and reporting structures may change over time based on corporate filings and organizational updates.